Hull M E, Kriner M, Schneider E, Maiman M
Division of Reproductive Endocrinology, State University of New York at Stony Brook, USA.
J Reprod Med. 1996 Jan;41(1):52-4.
Questions have been raised regarding the potential association of ovulation-inducing drugs and ovarian cancer. Worldwide there have been 13 cases of ovarian carcinoma reported to occur in women previously treated with ovulation-inducing drugs (clomiphene citrate and/or gonadotropins).
A 40-year-old woman complained of secondary infertility. She conceived after five cycles of human menopausal gonadotropins with intrauterine insemination. Eight months after cesarean delivery, she presented with right lower quadrant pain and a right adnexal mass. At exploratory laparotomy the patient was found to have a poorly differentiated papillary serous carcinoma of the ovary.
Ovarian carcinoma developed within 18 months of exposure to ovulation-inducing agents, human menopausal gonadotropins. It would be prudent to gather a registry of cases to assess the risk associated with human menopausal gonadotropins with or without gonadotropin-releasing hormone analogs.
关于促排卵药物与卵巢癌之间的潜在关联已引发诸多问题。全球范围内,已有13例卵巢癌病例报告称发生在先前接受过促排卵药物(枸橼酸氯米芬和/或促性腺激素)治疗的女性身上。
一名40岁女性主诉继发性不孕。她在接受五个周期的人绝经期促性腺激素联合宫腔内人工授精后怀孕。剖宫产术后八个月,她出现右下腹疼痛和右侧附件包块。在剖腹探查术中,发现该患者患有低分化乳头状浆液性卵巢癌。
在接触促排卵药物人绝经期促性腺激素后的18个月内发生了卵巢癌。收集病例登记资料以评估使用或未使用促性腺激素释放激素类似物的人绝经期促性腺激素相关风险是明智之举。